How AI Is Aiming at the Bad Math of Drug Development

Robert Marcus
Nov 29, 2021

Related news

Nov 9
,
2021
AI
Cleantech
Healthcare
Investment
Life Science
Press

Accenture (ACN) Announces Strategic Investment in Geneyx

Mar 15
,
2021
AI
Cleantech
Healthcare
Investment
Life Science
Press

The End of Silicon Valley as We Know It?

Nov 3
,
2021
AI
Cleantech
Healthcare
Investment
Life Science
Press

Pandemic has caused perfect storm for MedTech

Oct 12
,
2021
AI
Cleantech
Healthcare
Investment
Life Science
Press

Microsoft’s next moves: Biz dev and strategy leader Christopher Young is focusing on these key areas

Dec 8
,
2021
AI
Cleantech
Healthcare
Investment
Life Science
Press

390 Startup Failure Post-Mortems

Nov 1
,
2021
AI
Cleantech
Healthcare
Investment
Life Science
Press

Our Relationship with AI: Friend Or Foe? Summary of our Global Study

Apr 11
,
2021
AI
Cleantech
Healthcare
Investment
Life Science
Press

Ronald Cohen: “Mesurons l’impact comme on mesure les profits”

Dec 16
,
2021
AI
Cleantech
Healthcare
Investment
Life Science
Press

AI drug discovery platform raises Series B funding

Jan 11
,
2022
AI
Cleantech
Healthcare
Investment
Life Science
Press

Pfizer and PostEra collab in $250M AI lab deal

Feb 1
,
2022
AI
Cleantech
Healthcare
Investment
Life Science
Press

ALPHA10X Emerges from Stealth With $9.4 Million In Seed Funding

Feb 21
,
2022
AI
Cleantech
Healthcare
Investment
Life Science
Press

Intelligence Artificielle : l'UM6P signe un partenariat avec la start-up ALPHA10X

Feb 21
,
2022
AI
Cleantech
Healthcare
Investment
Life Science
Press

Innovative AI-powered Search and Discovery Platform; Interview With Robert Marcus